AdvaMed® Submits Comments on CY 2023 ESRD PPS Proposed Rule
AdvaMed® submitted comments to CMS the CY 2023 End Stage Renal Disease (ESRD) Prospective Payment System.
Coverage & Payment
Learn more about our Payment & Health Care Delivery Policy work.
AdvaMed® Urges CMS to Issue Proposed TCET Rule This Year, Offers Direction on Achieving Success for Medicare Beneficiaries to Receive Latest Medical Technologies
The Advanced Medical Technology Association® (AdvaMed®), the world’s largest trade association representing medical device manufacturers, urged the U.S. Centers for Medicare & Medicaid Services (CMS) to issue its proposed Transitional…
AdvaMed® Submits Comments on Genetic Testing in Oncology LCD
AdvaMed® submitted a letter to Medicare Administrative Contractors, Novitas and First Coast Service Options, regarding proposed LCDs on Genetic Testing in Oncology.
AdvaMed® Submits Comments on FY 2023 IPPS Proposed Rule
AdvaMed® submitted comments to CMS on the Fiscal Year 2023 Hospital Inpatient Prospective Payment System proposed rule.
AdvaMed® Comments on Proposed Delay of Radiation Oncology Model
AdvaMed® submitted comments to the Center for Medicare and Medicaid Services (CMS) on its Radiation Oncology (RO) Model proposed rule proposing to indefinitely delay the start date of the RO…
Medtech Value Framework
AdvaMed® launched a Strategic Value Initiative to develop an approach and principles for assessing the value of medical technologies that can be adopted by health systems, payers, medtech companies, and…
Diagnostic Tests Coding, Coverage, and Payment
AdvaMed® develops and advocates for sound payment policies that promote equitable patient access to diagnostic tests.
Medicare Coverage and Payment Policy
AdvaMed® develops strategies for improving Medicare coverage and payment systems and methodologies impacting patients, providers, and suppliers.
AdvaMed® Submits Comments on Local Coverage Determination of Skin Substitutes
AdvaMed® submitted a letter regarding proposed local coverage determinations entitled “Skin Substitutes for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcer.”
AdvaMed® Comments on Proposed CDC Clinical Practice Guideline for Prescribing Opioids
AdvaMed® urged CDC to recognize the critical role evidence-based and FDA-approved/cleared devices can and should play in improving pain management and reducing opioid-related harms.